- Technologist presentation
- Open Access
Is infarct location a prediction of valvular enhancement?
© Williams et al; licensee BioMed Central Ltd. 2010
- Published: 21 January 2010
- Aortic Valve
- Mitral Valve
- Tricuspid Valve
- Mitral Annulus
- Gadolinium Contrast
Every day in CMR, delayed hyperenhancement (DHE) is utilized for evaluation of the patient’s extent of myocardial damage from an infarction. In the past,following an MI, we have shown that DHE signal may be seen in the post-MI valvular apparati, not limited to the myocardium. Also, dilation of the mitral annulus was noted over time in some patients. However, it is not known if the infarction location influences which valves enhance, in particular, whether there is a local or a global influence on valvular enhancement.
We hypothesize that the location of the infarct does not influence which valves enhance.
One hundred-one (101) post-MI CMR examinations (chronic MI: 97%>6wks;3% acute<6 wks) were retrospectively reviewed for their infarct location, and whether mitral valves (MV), tricuspid valves (TV), and aortic valves (AV) exhibited any DHE signal after the administration of intravenous gadolinium contrast agents, either 0.2 mmol/kg Magnevist (Berlex, Wayne, NJ.) or 0.15 mmol/kg MultiHance (Bracco, Princeton, NJ). The areas observed were anterior, anterior septum, septum, inferior, inferior septum, lateral, anterior lateral, inferior lateral, and apical areas of the myocardium. The location of the infarct was then assigned anatomically to LAD, RCA, and the LCX coronary distributions.
The reason for valvular enhancement status post MI is not clearly understood. Using CMR DHE, and correlating the location of the areas of DHE signal, it suggests that the distribution of valvular enhancement is not influenced by the coronary artery involved. This points to a global rather than regional involvement of the valvular apparati.
This article is published under license to BioMed Central Ltd.